BlueWillow Biologics
Phase 1BlueWillow Biologics’ NanoVax® technology (W805EC oil-in-water adjuvant) is transforming the prevention and treatment landscape for infectious disease and pandemic preparedness. Our clinical-stage intranasal adjuvant and antigen delivery platform is the most advanced in development.
Founded
2007
Focus
BiologicsVaccines
About
BlueWillow Biologics’ NanoVax® technology (W805EC oil-in-water adjuvant) is transforming the prevention and treatment landscape for infectious disease and pandemic preparedness. Our clinical-stage intranasal adjuvant and antigen delivery platform is the most advanced in development.
Funding History
21Total raised: $35.6M
Grant$892KNIAIDMay 16, 2024
Grant$873KNIAIDDec 14, 2022
Grant$988KNIAIDAug 2, 2022
Grant$854KNIAIDJan 14, 2022
Company Info
TypePrivate
Founded2007
LocationAnn Arbor, United States
StagePhase 1
Contact
Sectors
SIMILAR COMPANIES
BASi Research Products
Pre-clinical · West Lafayette
Bay BioSciences
Pre-clinical · San Francisco
EydisBio
Pre-clinical · Cambridge
3Spine
Pre-clinical · Memphis
Belcher Pharmaceuticals
Pre-clinical · Miami
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile